Lexicon Pharmaceuticals is a biopharmaceutical company. Co. discovers the functions and pharmaceutical utility of genes and uses those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. Co. is also developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Co. is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. In addition, Co. is conducting preclinical research and development and preparing to conduct clinical development of compounds from several additional drug programs. We show 35 historical shares outstanding datapoints in our LXRX shares outstanding history coverage, used to compute LXRX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LXRX market cap history over the course of time is important for investors
interested in comparing LXRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LXRX versus a peer is one thing; comparing
LXRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LXRX can fluctuate over the course of history.
With this page we aim to empower investors researching LXRX by allowing them to research the LXRX market cap history. |
Free LXRX Email Alerts:
Video: The Importance of Market Cap
